Low-certainty evidence suggests that off-label fluoxetine may decrease weight compared with placebo .
However , low-certainty evidence suggests an increase in the risk for dizziness , drowsiness , fatigue , insomnia and nausea following fluoxetine treatment
BACKGROUND Fluoxetine is a serotonin reuptake inhibitor indicated for major depression .
It is also thought to affect weight control : this seems to happen through appetite changes result ing in decreased food intake and normalisation of unusual eating behaviours .
However , the benefit-risk ratio of this off-label medication is unclear .
OBJECTIVES To assess the effects of fluoxetine for overweight or obese adults .
Multicenter trial of fluoxetine as an adjunct to behavioral smoking cessation treatment.
The authors evaluated the efficacy of fluoxetine hydrochloride ( Prozac ; Eli Lilly and Company , Indianapolis , IN ) as an adjunct to behavioral treatment for smoking cessation . Sixteen sites r and omized 989 smokers to 3 dose conditions : 10 weeks of placebo , 30 mg , or 60 mg fluoxetine per day . Smokers received 9 sessions of individualized cognitive-behavioral therapy , and biologically verified 7-day self-reported abstinence follow-ups were conducted at 1 , 3 , and 6 months posttreatment . Analyses assuming missing data counted as smoking observed no treatment difference in outcomes . Pattern-mixture analysis that estimates treatment effects in the presence of missing data observed enhanced quit rates associated with both the 60-mg and 30-mg doses . Results support a modest , short-term effect of fluoxetine  on smoking cessation and consideration of alternative models for h and ling missing data
Low-certainty evidence suggests that off-label fluoxetine may decrease weight compared with placebo .
However , low-certainty evidence suggests an increase in the risk for dizziness , drowsiness , fatigue , insomnia and nausea following fluoxetine treatment
BACKGROUND Fluoxetine is a serotonin reuptake inhibitor indicated for major depression .
It is also thought to affect weight control : this seems to happen through appetite changes result ing in decreased food intake and normalisation of unusual eating behaviours .
However , the benefit-risk ratio of this off-label medication is unclear .
OBJECTIVES To assess the effects of fluoxetine for overweight or obese adults .